Paper Poster Presentations

At the ESCMID/ASM conference selected paper posters will be shown during two dedicated poster sessions.


Wednesday, 5 October 2022: 17:00 - 18:30

Thursday, 6 October 2022: 17:15 - 18:15


During these sessions the presenting author will be standing next to their poster and lively discussions are encouraged. Refreshments and snacks will be offered, while the sessions are taking place, for the presenters and attendees.


Poster instructions can be found below on this page.


The list of accepted abstracts can be found below:


Abstract number Abstract title Submitter
EA01 Time to change the complicated urinary tract infection primary endpoint? The problem and a potential solution Paul McGovern
EA02 Population pharmacokinetics of apramycin to support prediction of efficacious dose with first-in-human trial data Anna Chirkova
Abstract number Abstract title Submitter
EA03 Cefepime-taniborbactam and comparator activity in vitro against carbapenem-resistant Enterobacterales (CRE), carbapenem-resistant Pseudomonas aeruginosa (CRPA) and multidrug-resistant (MDR) Enterobacterales and P. aeruginosa from 2018-2020 surveillance Greg Moeck
EA04 Biological evaluation of novel phosphonate inhibitors targeting Pseudomonas aeruginosa elastase LasB Roya Shafiei
EA05 Octapeptins - independent antibiotic agents or antibiotic adjuvants to treat MDR/PmxR Gram-negative bacteria?  Johannes Zeugg
EA06 Developing a novel antimicrobial-phytochemical conjugate with antimicrobial activity against Streptococcus uberis, Enterococcus faecium and Enterococcus faecalis Jian Yang
EA07 A study of restoring tobramycin effectiveness toward resistant Gram-negative bacteria by encapsulate it in liposomal formulation containing methylglyoxal (Lip-MGO-TOB) Wed Alluhaim
EA08 DNV3837, a parenteral GI tract-targeted treatment for Clostridioides difficile infection Georges Gaudriault
EA09 Participant, geographic, and surgical factors are associated with clinical failure in registrational trials for complicated intraabdominal infection Tori Kinamon
EA10 BARDA’s Investments and priorities in product development to combat antimicrobial resistance Jessica Swenson
EA11 Resistance islands: a novel drug target Samantha McCarlie
EA12 Novel dual bacterial topoisomerases inhibitors with broad-spectrum antibacterial activity Martina Hrast
Abstract number Abstract title Submitter
EA13 Identifying the network of bactericidal interactions between mycobacterial respiratory chain complexes to develop fast-acting drugs for tuberculosis Greg Cook
EA14 Towards the discovery of new DDl inhibitors using a fragment-based drug discovery Rok Frlan
EA15 Inter-species interactions alter antimicrobial susceptibility in polymicrobial cultures Eva Bernadett Benyei
EA17 Penicillin binding protein inhibitors of EcPBP3 discovered using a modified phage display platform (Bicycles®) Hector Newmanok
EA18 Chemical-chemical interaction profiling reveals a Rod complex inhibitor Rinki Gupta
EA19 Characterisation of novel, non-covalent cyclic peptide (Bicycles®) inhibitors of PBP3s from important Gram-negative pathogens Nikolaos Bournakas
EA20 RECCE® 327 demonstrates bactericidal activity against several microbial species James Graham
EA21 Antibacterial, safety, efficacy and molecular mechanism-of-action of halogenated codonopsinine derivative (HCD1) against methicillin-resistant Staphylococcus aureus (MRSA) Saiful Azmi Johari
EA22 Organic derivatives of silichristin elicited potent antibacterial activity against penicillin-binding protein 3 of Pseudomonas aeruginosa in silico Jamiu Aribisala
EA23 Design of small-molecule drugs to target multiple bacterial tRNA synthetases Lorenzo Pavanello
EA24 WGS-based dual strategy for the Identification of key targets to enhance beta-lactam activity in Mycobacterium tuberculosis Francisco Olivença
EA25 Discovery of PK-188 as novel non-competitive inhibitor targeting NDM-1 and VIM metallo-β-lactamases Vidmantas Petraitis
Abstract number Abstract title Submitter
EA26 Fragment class with carbapenemase inhibition and antibacterial activity Daniel Norman
EA27 In vitro potency and selectivity of a novel class of outer membrane protein targeting antibiotics (OMPTA) that disassemble the lipopolysaccharide transport bridge (LptA) Carolin D'Arco
EA28 In vivo potency of a novel class of outer membrane protein targeting antibiotic (OMPTA) that disassemble the lipopolysaccharide transport bridge (LptA) Françoise Jung
EA29 In vitro bactericidal activity of NOSO 502: a novel action odilorhabdin antibiotic Alasdair MacGowan
EA30 Antibacterial interactions of NOSO-502 studied by checkerboard method using combinations with amikacin, ciprofloxacin, colistin, meropenem and tigecycline against Enterobacterales Alasdair MacGowan
EA31 Antimicrobial activity of ceftolozane/tazobactam and imipenem/relebactam in Dutch Pseudomonas aeruginosa isolates obtained from patients at the ICU, Pulmonology and Urology Depts. collected during 10 years of surveillance Peter Croughs
EA32 Metallobiotics: A new class of antimicrobial agents? Mark Blaskovich
EA33 Conjugated oligoelectrolytes – a novel antibiotic platform with activity against nontuberculous mycobacteria Kaixi Zhang
Abstract number Abstract title Submitter
EA35 Recurring problems and mitigation strategies in the development of monoclonal antibodies against AMR pathogens: a report from the COMBINE Expert Workshop Linda Marchioro
EA36 Lysins as promising antibacterial therapeutics against uropathogenic Escherichia coli Syed Ahmed
EA37 Monoclonal antibodies against BauA and OmpW2 disrupt growth, prevent sepsis, and promote survival of mice infected with Acinetobacter baumannii Daniel Zurawski
EA38 HITidentify: Immune evasion target identification for the development of novel antibacterial nanobodies Bharathi Sundaresh
EA39 Cannabidiol (CBD) as novel non-traditional antimicrobial candidate targeting methicillin-resistant and vancomycin-intermediate Staphylococcus aureus Vidmantas Petraitis
Abstract number Abstract title Submitter
EA40 P. aeruginosa grown in printable cystic fibrosis model biofilms suitable for high-throughput screening of antibiotics interactions Goodness Ogechi Osondu-Chuka
EA41 Antisense based anti-adhesive strategy against bacterial urinary tract infection Elnaz Harifi Mood
EA42 Antibody-antibiotic conjugate for melioidosis Adam Taylor
EA43 Polymersome encapsulation to enhance antibiotic delivery for the treatment of melioidosis Kimberley Wright
EA44 Romo1-derived antimicrobial peptide is a new antimicrobial agent against multidrug-resistant bacteria in a murine model of sepsis Young Do Yoo
EA45 Pharmacodynamics of bacterial efflux pump inhibitors (EPI): proof of concept studies Alasdair MacGowan
EA46 Activity of the novel engineered antimicrobial peptide PLG0206 against non-fermenting Gram-negative rods Ian Morrissey
EA47 Organoselenium inhibitors reduce ureolysis and viability of C. neoformans and H. pylori Agnieszka Grabowiecka
EA48 Ebselen derivatives as picomolar inhibitors of bacterial ureases Wojciech Tabor
EA49 The bacterial itaconate degradation pathway: an immune system evasion mechanism and antimicrobial target Jacob Pierscianowski
EA50 A novel, clinically relevant polymyxin, SPR206, eradicates all Gram-negatives associated with wound infection and prevents infection in vivo Daniel Zurawski
EA51 Using guided antimicrobial peptides to modulate antimicrobial resistance patterns in Helicobacter pylori Patrick Ortiz
EA52 In vitro efficacy and pharmacodynamics of novel 1,10-phenanthroline-5,6-dione-based metal compounds against Acinetobacter baumannii MDR clinical strains Ingrid Peregrino
EA53 Efficacy of cefiderocol in experimental Stenotrophomonas maltophilia pneumonia in persistently neutropenic rabbits Vidmantas Petraitis
EA54 The combination therapy with polymyxin B nonapeptide eradicates persisters Jihyeon Kim
Abstract number Abstract title Submitter
EA56 Rapid endpoint method for the quantification of Mycobacterium tuberculosis (Mtb) subjected to three different treatment regimens within the hollow fibre system (HFS) Stephanie Sandiford
EA57 Pharmacodynamics of WCK 4282 (high dose cefepime plus tazobactam) against βlactamase producing E. coli Alasdair MacGowan
EA58 Newly synthesized 5-pyrazolyl substituted 2,4-thiazolidinedione as potential anti-inflammatory and antimicrobial agent Yulian Konechnyi
EA59 Preclinical development of CRS0393 as a novel antimycobacterial agent that inhibits MmpL3 Urs Ochsner
EA60 A standard protocol for the murine pneumonia model to evaluate treatments for AMR lung infections Jon Ulf Hansen
EA61 In vivo pharmacodynamic evaluation of meropenem-nacubactam in murine thigh and lung infection models against Klebsiella pneumoniae (KPN) containing OXA-48-like enzymes Alexander Lepak
EA62 In vivo pharmacodynamic evaluation of CRS0540 in the murine thigh and lung infection models against Staphylococcus aureus Alexander Lepak
EA63 Preclinical evaluation of apramycin as a drug candidate for Mycobacterium abscessus infections Sven Hobbie
EA64 Novel bacterial topoisomerase inhibitor gepotidacin demonstrates absence of fluoroquinolone-like arthropathy in juvenile rats Cindy Fishman
EA64A Murine vaginal infection models with MDR Neisseria gonorrhoeae isolates for pharmacology studies Lynn Miesel
Abstract number Abstract title Submitter
EA65 Trends in antimicrobial resistance amongst pathogens isolated from blood and cerebrospinal fluid cultures in Pakistan (2011-2015): A retrospective cross-sectional study Nida Javaid
EA66 Sticker reminder for  IV-to-PO  switching  of  fluoroquinolone therapy; preliminary results of a cluster-randomized controlled trial Pinyo Rattanaumpawan
EA68 Genotypic characterization of antimicrobial resistant Staphylococcus species in raw camel milk from Garissa County, Kenya Elly Kirwa
EA69 Real-world analysis of new antibiotic use at a US medical center with multi-drug resistant (MDR) Pseudomonas aeruginosa (PSA) but a paucity of carbapenemase-producing Enterobacterales (CPE) Alexander Lepak
EA69A Treatment of AmpC-producing Enterobacterales; Are we overusing carbapenems? Elaine Houlihan
Abstract number Abstract title Submitter
EA70 Improving the accuracy of in vitro antimicrobial testing with simulated body fluid Connagh Redmond
EA71 BPO: the Bioassay Protocol Ontology, a semantic approach to elevate the reusability of AMR-related drug discovery data Yojana Gadiya
EA73 Correlation between antimicrobial resistance and immune-depression in pediatrics: a retrospective study from the Bambino Gesù Children Hospital of Rome Danielle Domo
EA74 Cd resistance leads antibiotic resistance in bacteria of host and non-host environment Juoae Chang

Poster Instructions



A1 Portrait

A1 size is 841 x 594mm - ( 33.1 x 23.4 inches )


Please make sure to put your poster number on your poster!

  • Posters will be adjusted with provided pins
  • Self adhesive circles will be provided and can be attached to the rear of the posters.
  • The material of the boards is Velcro and with the needles all kinds of poster materials can be attached

Printing options


ESCMID is not working with an official provider, however here are some suggestions from the convention bureau:


Snap Printing: (taxi drive away)

Hadleighprint: (30 second drive or 25 minute walk)

Mullen Print: (taxi drive away)


For questions, please email conferences[at]